Sign in or create an account to add this stock to your watchlist.
About Deciphera Pharmaceuticals (NASDAQ:DCPH)
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-8.38
Forward P/E Ratio-9.41
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$5.05 per share
Price / Book5.01
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals (NASDAQ:DCPH) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.04. View Deciphera Pharmaceuticals' Earnings History.
What price target have analysts set for DCPH?
6 Wall Street analysts have issued 1-year price objectives for Deciphera Pharmaceuticals' stock. Their predictions range from $30.00 to $57.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $43.3333 in the next year. View Analyst Ratings for Deciphera Pharmaceuticals.
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), TESARO (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
- Dr. Oliver Rosen, Chief Medical Officer (Age 54)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
- Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
When did the company's lock-up period expire?
Deciphera Pharmaceuticals' lock-up period expired on Tuesday, March 27th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its initial public offering on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
News articles about DCPH stock have trended somewhat positive on Friday, according to Accern. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Deciphera Pharmaceuticals' major shareholders?
Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (2.52%), BlackRock Inc. (1.53%), Opaleye Management Inc. (1.12%), Lord Abbett & CO. LLC (1.07%), JPMorgan Chase & Co. (0.88%) and Millennium Management LLC (0.74%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.
Which institutional investors are selling Deciphera Pharmaceuticals stock?
Which institutional investors are buying Deciphera Pharmaceuticals stock?
DCPH stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Redmile Group LLC, BlackRock Inc., JPMorgan Chase & Co., Eversept Partners LLC, Lord Abbett & CO. LLC, A.R.T. Advisors LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Deciphera Pharmaceuticals.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $25.31.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $842.56 million. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (DCPH)MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.61%
Institutional Ownership Percentage: 48.73%
Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/2/2017||New Leaf Venture Management Ii||Major Shareholder||Buy||375,000||$17.00||$6,375,000.00|| |
Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines
Deciphera Pharmaceuticals (NASDAQ:DCPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Deciphera Pharmaceuticals (NASDAQ:DCPH) Income Statement, Balance Sheet and Cash Flow Statement
Deciphera Pharmaceuticals (NASDAQ DCPH) Stock Chart for Friday, May, 25, 2018